Ber-H2 (CD30) Immunohistochemical Staining of Human Fetal Tissues by Tamiolakis, D et al.
Int. J. Biol. Sci. 2005 1 
 
135
International Journal of Biological Sciences 
ISSN 1449-2288 www.biolsci.org 2005 1(4):135-140 
©2005 Ivyspring International Publisher. All rights reserved 
Research paper 
Ber-H2 (CD30) Immunohistochemical Staining of Human Fetal Tissues  
D Tamiolakis1, N Papadopoulos2, M Lambropoulou2, J Venizelos2, D Verettas3, P Tsikouras4, G Koutsougeras5,                       
H Papadopoulos2, A Karpouzis6 and C Kouskoukis6  
1 Department of Cytology, General Hospital of Chania, Crete, Greece 
2 Department of Histology - Embryology, Democritus University of Thrace, Greece 
3 Department of Orthopedics, Democritus University of Thrace, Greece 
4 Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece 
5 Department of Obstetrics and Gynecology, General Hospital of Alexandroupolis, Greece 
6 Department of Dermatology, Democritus University of Thrace, Greece 
Corresponding address: Papadopoulos Nikolaos, Ass. Professor in Histology-Embryology, Democritus, University of Thrace, 
Dragana, 68 100 Alexandroupolis, Greece. Fax: +3025510-30526 E-mail: npapad@med.duth.gr 
Received: 2005.05.26; Accepted: 2005.08.23; Published: 2005.10.01 
OBJECTIVE: CD30 antigen has long been considered to be restricted to the tumour cells of Hodgkin’s disease and of 
anaplastic large cell lymphoma as well as to T and B activated lymphocytes. It is now apparent that the range of normal 
and neoplastic cells, which may express CD30 antigen, is much wider than was at first thought. In order to gain insight 
into the physiological function of CD30 antigen, we studied the distribution of its expression in the tissues of fetuses 
from week 8th to week 16th. 
MATERIALS AND METHODS: We investigated the immunohistochemical expression of CD30 antigen in paraffin-
embedded tissue samples representing all systems from 30 fetuses after therapeutic abortion at 8th to 10th and 12th to 16th 
week of gestation, respectively, using the monoclonal antibody Ber-H2. 
RESULTS: Our results demonstrated that CD30 is expressed early in human fetal development (8th to 10th week of 
gestation) in several fetal tissues derived from all three germ layers (gastrointestinal tract, special glands of the 
postpharyngeal foregut, urinary, musculoskeletal, reproductive, nervous, endocrine systems), with the exception of the 
skin and hematolymphoid system (thymus), in which the antigen is expressed later on (10th week onwards). Expression 
of CD30 was restricted to the hematolymphoid system in the 12-16 weeks of gestation. No expression of the marker was 
observed in the respiratory and cardiovascular systems during the entire period examined. 
CONCLUSIONS: CD30 antigen is of importance in cell development, and proliferation. It is also pathway-related to 
terminal differentiation in many fetal tissues and organs.  
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1.  INTRODUCTION  
CD30 antigen, a member of the tumor necrosis factor 
(TNF) receptor superfamily, [1-3] was originally identified 
as a cell surface antigen on primary  and cultured 
Hodgkin’s and Reed-Sternberg cells by use  of the 
monoclonal antibody Ki-1 [4,5]. CD30 antigen normally is 
expressed by a subset (15–20%) of CD3+ T cells after 
activation by a variety of stimuli [6]. Its expression is 
stimulated  by interleukin (IL)-4 during lineage 
commitment of human naïve T cells and is augmented by 
the presence of CD28 costimulatory  signals [7,8]. CD30 
also is expressed at variable levels in different  non-
Hodgkin’s lymphomas (NHL) as well as in several virally 
transformed T and B cell lines [8]. In particular, CD30 is a 
specific marker of a subset of peripheral T cell NHLs 
known  as anaplastic large cell lymphomas (ALCL) [5]. 
More recently,  CD30 preferential expression has been 
detected on a subset of tissue and circulating CD4+ and 
CD8+ T cells producing mainly  Th2 cytokines in 
immunoreactive conditions [8].  
CD30 appears to have an important 
immunoregulatory role in normal  T cell development. 
Within the thymus, CD30L is highly expressed  on 
medullary thymic epithelial cells and on Hassal’s 
corpuscles [9].  
Pallesen and Hamilton-Dutoir [10] were the first to 
report CD30 expression outside of the lymphoid tissue in 
12 out of 14 cases of primary or metastatic embryonal 
carcinoma (EC) of the testis, by immunostaining with the 
monoclonal antibodies (MAbs) Ber-H2 and Ki-
1.  Subsequently, several investigators have confirmed 
their results and have detected CD30 in these carcinomas 
at the protein [11-14] and the mRNA level [8]. Two reports 
demonstrated CD30 expression in 4/21 and 4/63 cases of 
testicular and mediastinal seminoma, and in the 
seminomatous components of 7/14 cases of mixed germ 
cell tumours of the testis, respectively [15, 16]. Suster et al. 
detected the CD30 antigen in 6/25 yolk sac tumours of the 
testis and mediastinum [16]. The expression of the CD30 
antigen has also been reported in other non-lymphoid 
tissues and cells, such as soft tissue tumours [17] decidual 
cells [18,19], lipoblasts [20], myoepithelial cells [21], 
reactive and neoplastic vascular lesions [22], 
mesotheliomas [23], cultivated macrophages, and two 
histiocytic malignancies [24].   
  The fact that the CD30 molecular can mediate signal 
for cell proliferation or apoptosis [2] prompted us to 
perform a systematic investigation of CD30 antigen 
expression in non hematopoietic embryonal tissues during 
proliferation and differentiation stages, beginning with 
the epithelial cells of the developing intestinal crypts [8]. 
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distribution in embryonal tissues using 
immunohistochemistry, from week 8th   o n w a r d s ,  i n  a n  
effort to uncover patterns of expression that may elucidate 
the potential role of the marker during development 
stages. 
2.  MATERIALS AND METHODS 
Tissue Procurement 
The tissue material (30 fetuses) used in this study 
was obtained from the files of the Department of 
Histology - Embryology at the University of Thrace. 
Samples representing a wide variety of tissues from all 
systems were collected from 30 fetuses (15 at 8th to 10th 
week of gestation and 15 at 14th to 16th, respectively) after 
therapeutic abortion. The organs used did not show any 
evidence of morphological abnormality.   The Regional 
Ethics Committees approved the study.  Written informed 
consent was obtained from all individuals and the 
procedures followed accorded with institutional 
guidelines. 
Sections of tissue roughly 3-mm thick were fixed in 
10% buffered formaldehyde for 7 hours then subjected to 
routine processing and paraffin embedding. Slides were 
obtained in all cases, and stained with hematoxylin-eosin 
(H-E), PAS, Giemsa and Gomori for morphological 
evaluation. 
Monoclonal antibody and immunohistochemical staining  
Antigen retrieval from formalin-fixed, paraffin-
embedded tissue was performed by heating unstained 
sections immersed in DAKO Target Retrieval Solution 
(DAKO, Carpintera, CA) according to the manufacture’s 
instructions. A modified labeled avidin-biotin 
immunohistochemical staining was performed with the 
use of the LSAB-2 System Peroxidase Kit (DAKO) on 
DAKO Autostainer, according to the manufacturer’s 
instructions. In short, deparafinized sections were 
incubated with 3% hydrogen peroxide for 5 min, followed 
by 10-min incubation with 1:20 solution of Ber-H2 MAb 
(Novocastra Laboratories Ltd., Newcastle, UK). That was 
followed by sequential 10-min incubations with a 
biotinylated link antibody and peroxidase-labeled 
streptavidin. Staining was completed after a 10-min 
incubation with DAKO Liquid 3,3’-diaminobenzidine 
Substrate-Chromogen System utilizing 3,3’-
diaminobenzidine (DAB) chromogen. Biopsied lymph 
nodes of Hodgkin’s disease were used as controls. All 
cases were coded, and the grading of the immunostaining 
was performed on a sliding scale of 1+ to 4+ according to 
the percentage of reactive cells (0 = no staining, 1+ = 1% to 
25%; 2+ = 26% to 50%; 3+ = 51% to 75%; 4+ > 76%).  
3.  RESULTS 
Five microscopic fields of each tissue were evaluated 
in each case. The results of the immunostaining are 
summarized in Table 1. Two observers examined the 
sections independently, and positive cellular staining was 
manifested as fine brown cytoplasmic granularity and/or 
nuclear expression. Nuclear expression of the antigen was 
observed in the case of long bones development during 
endochondral ossification, and this is a far unreported 
location of CD30. Maria Trovato et al have reported 
nuclear expression of CD30 Ligand (CD30L) in oncocytic 
adenomas of the thyroid [25]. Immunostaining of tissue 
sections revealed the presence of CD30 antigen in many 
tissue types in variable abundance, mainly during the first 
period (8th to 10th week of gestation). Especially, in the 
gastrointestinal tract, positive staining for CD30 was 
observed in the epithelial cells (Fig. 1) of the developing 
primitive crypts (epithelial downgrowths into the 
mesenchyme between the villi) of the small intestine. For 
the special glands of the postpharyngeal foregut, a weak 
cytoplasmic expression of CD30 was noticed in 
hepatocytes sparing the haematopoietic cells (Fig. 2), 
whereas a strong positivity was observed in the epithelial 
cells of the pancreatic ducts and acini. In the urinary 
system CD30 was expressed in the epithelial cells of the 
tubules and collecting ducts in the cortex of the kidney 
(Fig. 3), and in the epithelial cells lining the pelvis. In the 
musculoskeletal system (long bones), during the process 
of intracartilagineous (endochondral) ossification, positive 
CD30 cells were noted in the condensation of 
mesenchymal cells that constituted the perichondrium of 
the cartilagenous masses, at the site of the primary 
ossification centers (Fig. 4). In the intramembranous 
(mesenchymal) ossification (flat bones), positive CD30 
polygonal mesenchymal cells were observed within a 
loosely organized connective tissue stroma. In the 
reproductive system in both male and female embryos at 
10th week of gestation, staining for CD30 antigen was 
limited to a population of cuboidal or elongated cells 
distributed within the cortex for the ovary (Fig. 5), and 
medulla for the testis In the nervous system (cerebral 
cortex and cerebellum), CD30 was detected in cerebral 
cortical neurons (Fig. 6), and Purkinje cells. In the 
endocrine system (adrenal gland), medullary cells showed 
a strong cytoplasmic positivity for CD30 antigen, sparing 
the cortex (Fig. 7). In the haematolymphoid system 
(thymus), both thymic epithelial cells (TEC) and Hassal’s 
corpuscles in the medulla showed high CD30 expression 
(Fig. 8). In the thymic cortex, staining was limited to a 
population of flattened, elongated cells located under the 
connective tissue capsule of the organ. This is consistent 
with the observation that human thymus is not 
completely differentiated before week 13th of gestation, 
when the corticomedullary junctions and the first Hassal 
corpuscles become visible. In the skin of the 10-week 
fetuses, in which the epidermis is comprised of only 2 cell 
layers, CD30 was expressed in the cells of the basal layer 
only (Fig. 9). In 16-week fetuses, staining was 
predominantly observed in the developing skin adnexa 
(basal cells of epidermal buds), and in occasional basal 
keratinocytes (Fig. 10). 
Other tissues 
The immunohistochemical control for the detection 
of CD30 antigen in the developing respiratory and 
cardiovascular system was negative.   
4.  DISCUSSION  
The value of the CD30 antigen as a diagnostic marker 
for Hodgkin's lymphoma and anaplastic large cell 
lymphoma is well documented [4,5,26]. However, the 
function of this cytokine receptor in Hodgkin's lymphoma 
and other CD30-positive diseases is still not clear.  
CD30 appears to have an important 
immunoregulatory role in normal T cell development.  In 
normal cells, this transmembrane glycoprotein can be 
induced on B and T lymphocytes by mitogen stimulation 
or viral transformation [8].  cDNA cloning has revealed 
that the CD30 protein is a cytokine receptor of the tumor Int. J. Biol. Sci. 2005 1 
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necrosis factor receptor superfamily [1,27], the ligand of 
which belongs to the tumor necrosis factor family [8]. 
Recent in vitro data indicate that the CD30 receptor-
ligand complex can mediate signals for cell proliferation, 
apoptosis and cytotoxicity in lymphoid cells [29].  During 
embryogenesis, CD30 could be found in derivatives of all 
three germ layers; however, this expression was not 
ubiquitous. Ectodermal derivatives that contained CD30 
included cells of the central nervous system, medulla of 
the adrenal gland, and epidermis [8]. Mesodermal tissues 
expressing CD30 included kidney, primary ossification 
centers, and gonads. Intestine, liver, pancreas, and 
thymus, endoderm-derived tissues, also expressed CD30 
antigen [8]. 
First our findings are of significance with regard to 
t h e  s u p p o r t e d  o r i g i n  o f  R - S  c e l l s .  C a r e  m u s t  b e  t a k e n  
when drawing histogenetic conclusions based on the 
identification of a single marker in different cell types [8]. 
Shared expression of CD30 antigen does not necessarily 
relate Hodgkin and R-S cells to activated lymphocytes [8]. 
The identification of this antigen in cells as apparently 
disparate as activated lymphocytes, R-S cells and now 
human epithelial cells of the developing fetal  tissues 
suggests that previous theories as to the nature of the 
CD30 antigen must be re-examined. The Hodgkin and 
Reed-Sterberg cells are indeed lymphocytes as they harbor 
r e a r r a n g e d  i m m u n o g l o b u l i n  i n  m o r e  t h a n  9 0 %  o f  c a s e s  
and T cell receptors [28]. Although the expression of CD30 
antigen may indicate a relationship between these cell 
types, it is likely to be less straightforward than was 
previously supposed. Identification of the normal 
physiologic role of CD30 antigen is thus made even more 
imperative if these relationships are to be understood.  
A second point is that outside the lymphatic system, 
CD30 antigen expression in the epithelial cells of 
developing fetal tissues can mediate signals for cell 
proliferation and differentiation in a region where other 
cell types grow throughout life for example in the case of 
intestinal cryptae cells we refer to stem, goblet, Paneth 
and enteroendocrine cells [7, 8, 11].  
Third, CD30 also appears to be expressed in a 
selected group of terminally differentiated cells, which are 
responsive to hormonal stimulation (fetal skin 
keratinocytes) [12, 16, 17]. This variation of expression 
suggests a possible role for hormones, preferably 
progesterone, in the regulation of CD30 expression [17]. 
This would be a novel mechanism of CD30 induction 
other than neoplastic transformation and viral infection of 
lymphocytes. In our previous investigation concerning the 
developing intestinal crypts, the demonstration of the 
large Reed-Sternberg like cells in the developing crypts 
within a lymphoplasmacytic infiltrate, in the same way 
that similar Reed-Sternberg like cells are observed in the 
reactive lymph nodes especially within the parafollicular 
areas, is evidence that such cells might represent the 
physiologic counterpart of true Reed- Sternberg cells [8]. 
Our findings of Ber-H2 staining of fetal tissues and 
organs could well be added to the list of non- lymphoid 
tissues and cells normal and neoplastic expressing CD30 
antigen. However, it is also possible that the observed 
staining could represent a false positive reaction related to 
fixation and paraffin processing, although in the study by 
Schwarting et al [30] there was generally little difference 
between the results on frozen and paraffin sections. 
Nevertheless, in routine diagnostic practice, only 
formalin-fixed material is generally available for study 
and thus we conclude that the presence of positive 
staining cells should not automatically lead to a diagnosis 
of lymphoma.  
The possibility that CD30 antigen is an oncofetal 
antigen is supported by our positive findings in fetal 
tissues. We have been able to investigate several tissues 
from a number of fetuses from 8th gestational week 
onwards. Pallesen and Hamilton-Dutoit [10] examined 
CD30 expression in normal adult, neonatal and fetal 
(week 28) testes, as well as other tissues (brain, spinal 
cord, lung, gut, kidney, erythropoietic tissue, muscle, 
bone and connective tissue) from fetuses of 11 and 12 
weeks gestational age, with negative results.  This is the 
first demonstration of CD30 in epithelial cells in fetal 
tissue. Our findings together with reported positive 
staining seen in placenta [18,19] suggests that the antigen 
is expressed by epithelial proliferating and differentiating 
cells of other than lymphoid origin. Clearly the extent of 
expression of CD30 antigen in embryonal tissues warrants 
further investigation.  
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FIGURES & TABLE 
Figure 1. Small intestine: CD30 expression in the epithelial 
cells at the bottom of the developing primitive crypts. 
Immunostain X 200. 
 
Figure 2. Liver: CD30 is expressed in liver parenchymal cells, 
but not in hematopoietic cells. Immunostain X 200. 
 
Figure 3. Kidney: CD30 expression in the epithelial cells of 
tubules and ducts in the fetal kidney (cortex). Immunostain X 
200. 
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Figure 4. Intracartilagineous ossification: CD30 positive cells 
of the perichondrium at the site of primary ossification center 
Immunostain X 200. 
 
Figure 5. Ovary: Cuboidal or elongated CD30 positive cells in 
the cortex of the ovary. Immunostain X 200. 
 
Figure 6. Neural tissue: In the cerebral cortex, CD30 was 
expressed predominantly by neurons near the surface. 
Immunostain X 200. 
 
Figure 7. Adrenal gland: Note strong staining for CD30 in 
medullary cells. Immunostain X 200. 
 
Figure 8. Thymus: CD30 immunoreactive Hassal’s corpuscles 
in the thymic medulla. Immunostain X 400. 
 
Figure 9. Skin: The skin of a 10
th week fetus showing 
restriction of CD30 expression in the basal layer. Immunostain 
X 200. 
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Figure 10. Skin: The skin of a 16
th week fetus showing restriction 
of CD30 expression in developing skin adnexa (basal cells of 
epidermal buds), and in occasional basal keratinocytes. 






TABLE 1. Expression of CD30 fetal tissues 
 